Skip to content

Verigene Respiratory Virus Nucleic Acid Test on the Verigene SP System

by Nanosphere, Inc.

510(k) K093337

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Special NumberK093337 Date17 Nov 2009ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
OCC
Device Class
Class II
Regulation
21 CFR Part 866.3980
Advisory Committee
Microbiology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Verigene Respiratory Virus Nucleic Acid Test on the Verigene SP System is a Respiratory Virus Panel Nucleic Acid Assay System, designed for qualitative detection and identification of multiple respiratory virus nucleic acids in nasopharyngeal swab specimens. It functions as a multiplex test to simultaneously identify Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) nucleic acids, aiding in the differential diagnosis of respiratory infections. The assay leverages nucleic acid detection technology to provide rapid, laboratory-based results for clinical decision-making.

This test is intended for use on the Verigene SP System and is supplied as a single-use, in vitro diagnostic device. It is classified under FDA device class 2 and regulated under the 866.3980 regulation, with an FDA 510(k) clearance (K093337) granted under the Microbiology advisory committee. Specimens are processed in a clinical laboratory setting, and results should not be used as the sole basis for treatment or exclusion of infection, particularly for Influenza C virus, which is not detected by this assay. Sterility and proper storage conditions are critical for maintaining assay integrity.

Other devices from Nanosphere, Inc.

See all devices from Nanosphere, Inc. →

Questions

AI-generated answers, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What viruses does the Verigene Respiratory Virus Test detect?

    The Verigene Respiratory Virus Test is designed to detect and identify nucleic acids from Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens. It does not detect Influenza C virus, so results should not be used as the sole basis for excluding infection from this virus.

  • How is the Verigene Respiratory Virus Test supplied and used?

    The Verigene Respiratory Virus Test is supplied as a single-use, in vitro diagnostic device intended for use on the Verigene SP System. It is processed in a clinical laboratory setting, where it provides rapid, multiplex nucleic acid detection for clinical decision-making. The test requires laboratory infrastructure and trained personnel to operate the Verigene SP System.

  • Is sterility and proper storage important for this test?

    Yes, sterility and proper storage conditions are critical for maintaining the integrity of the Verigene Respiratory Virus Test. The device must be stored under conditions that preserve its functionality, as contamination or improper handling could compromise the accuracy of the results. Always follow the manufacturer’s guidelines for storage and handling.

  • Can the Verigene Respiratory Virus Test be reused?

    No, the Verigene Respiratory Virus Test is designed as a single-use device. Each test kit is intended for one-time use only, ensuring accuracy and preventing cross-contamination between specimens. Discard any unused portions after testing.

  • What regulatory approval does the Verigene Respiratory Virus Test hold?

    The Verigene Respiratory Virus Test holds FDA 510(k) clearance (K093337) under the Microbiology advisory committee, classified as a Class 2 device regulated under FDA regulation 866.3980. This clearance indicates that the device has been deemed substantially equivalent to a legally marketed predicate device.